Olivier Pellerin

Prof. Olivier Pellerin


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
Valérie VilgrainValérie Vilgrain
Valérie Vilgrain
HPHelena Pereira
Helena Pereira
EAEric Assenat
Eric Assenat
BGBoris Guiu
Boris Guiu
AIAlina Diana Ilonca
Alina Diana Ilonca
LMLysiane Marthey
Lysiane Marthey

5 June 2017 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
Dimitrios FilippiadisDimitrios Filippiadis
Dimitrios Filippiadis
CBC. Binkert
C. Binkert
OPOlivier Pellerin
Olivier Pellerin
RHR. T. Hoffmann
R. T. Hoffmann
AKA. Krajina
A. Krajina
PPP. L. Pereira
P. L. Pereira

28 April 2015 in JAMA
Verified
Journal Article
Open access
PDF file
PMPatrick Mismetti
Patrick Mismetti
SLSilvy Laporte
Silvy Laporte
OPOlivier Pellerin
Olivier Pellerin
PEPierre-Vladimir Ennezat
Pierre-Vladimir Ennezat
FCFrancis Couturaud
Francis Couturaud
GMGuy Meyer
Guy Meyer
This randomized trial compares the effects of a retrievable inferior vena cava filter plus anticoagulation with anticoagulation alone for prevention of recurren

3 February 2017 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
JPJ T Powell
J T Powell
MSM J Sweeting
M J Sweeting
PUP Ulug
P Ulug
JBJ D Blankensteijn
J D Blankensteijn
FLF A Lederle
F A Lederle
CCC Cousins
C Cousins
The erosion of the early mortality advantage of elective endovascular aneurysm repair (EVAR) compared with open repair of abdominal aortic aneurysm remains without a satisfactory explanation. An individual-patient data meta-analysis of four multicentre randomized trials of EVARversus open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related mortality and reintervention. The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5·5 years). Early (0–6 months after randomization) mortality was lower in the EVAR groups (46 of 1393 versus 73 of 1390 deaths; pooled hazard ratio 0·61, 95 per cent c.i. 0·42 to 0·89; P = 0·010), primarily because 30-day operative mortality was lower in the EVAR groups (16 deaths versus 40 for open repair; pooled odds ratio 0·40, 95 per cent c.i. 0·22 to 0·74). Later (within 3 years) the survival curves converged, remaining converged to 8 years. Beyond 3 years, aneurysm-related mortality was significantly higher in the EVAR groups (19 deaths versus 3 for open repair; pooled hazard ratio 5·16, 1·49 to 17·89; P = 0·010). Patients with moderate renal dysfunction or previous coronary artery disease had no early survival advantage under EVAR. Those with peripheral artery disease had lower mortality under open repair (39 deaths versus 62 for EVAR; P = 0·022) in the period from 6 months to 4 years after randomization. The early survival advantage in the EVAR group, and its subsequent erosion, were confirmed. Over 5 years, patients of marginal fitness had no early survival advantage from EVAR compared with open repair. Aneurysm-related mortality and patients with low ankle : brachial pressure index contributed to the erosion of the early survival advantage for the EVAR group. Trial registration numbers: EVAR-1, ISRCTN55703451; DREAM (Dutch Randomized Endovascular Aneurysm Management), NCT00421330; ACE (Anévrysme de l'aorte abdominale, Chirurgie versus Endoprothèse), NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), NCT00094575.

1 December 2012 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
MLMingDe Lin
MingDe Lin
OPOlivier Pellerin
Olivier Pellerin
NBNikhil Bhagat
Nikhil Bhagat
PRPramod P. Rao
Pramod P. Rao
RLRomaric Loffroy
Romaric Loffroy
JGJean-François Geschwind
Jean-François Geschwind

1 July 2015 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
ADA. Dohan
A. Dohan
Luc DarnigeLuc Darnige
Luc Darnige
MSM. Sapoval
M. Sapoval
OPOlivier Pellerin
Olivier Pellerin